Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) is one of the best performing pharma stocks in 2025. On January 7, Truist raised ...

The US regulator has approved a new use for Amgen’s blockbuster bone drug Xgeva, to prevent fractures in patients with newly-diagnosed multiple myeloma with bone metastases. Xgeva (denosumab) has ...

Samsung Bioepis has started direct commercialisation of Byooviz, a biosimilar to Genentech’s Lucentis (ranibizumab), in ...

Teva Pharmaceutical Industries Ltd ADR has reached a significant milestone, with its stock hitting a 52-week high at $32.02. This achievement marks a notable recovery and growth trajectory for the ...

Denosumab is a monoclonal antibody that inhibits bone resorption and is widely used across oncology and osteoporosis-related ...

Amneal wins FDA approval for two denosumab biosimilars, expanding lower-cost treatment options for bone loss and cancer patients.

Teva Pharmaceutical Industries recently reported third-quarter 2025 earnings that exceeded analysts’ expectations, advanced ...

Amneal Pharmaceuticals has just seen its fair value estimate nudged to US$14.00 from US$13.80, a small but meaningful reset that ties directly to how the latest quarterly numbers stack up against ...

Samsung Bioepis has begun direct commercialization of Byooviz in Europe. Byooviz is a biosimilar to Lucentis’ (ranibizumab).

FDA approves new denosumab biosimilars, enhancing treatment options for osteoporosis and bone metastases while driving ...

H.R. 875 – Jeremy and Angel Seay and Sergeant Brandon Mendoza Protect Our Communities from DUIs Act of 2025 (June 24, 2025) H.R. 275 – Special Interest Alien Reporting Act of 2025 (June 24, 2025) S.J.

They have also shared an outlook on pharma, telecom, internet platforms, banking, metals and consumer sectors, alongside ...